Pseudomyxoma peritonei (PMP) is a rare disease characterized by extensive peritoneal implantation and mass secretion of mucus after primary mucinous tumors of the appendix or other organ ruptures. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is currently the preferred treatment, with excellent efficacy and safety, and is associated with breakthrough progress in long-term disease control and prolonged survival. However, the high recurrence rate of PMP is the key challenge in its treatment, which limits the clinical application of multiple rounds of CRS-HIPEC and does not benefit from conventional systemic chemotherapy. Therefore, the development of alternative therapies for patients with refractory or relapsing PMP is critical. The literature related to PMP research progress and treatment was searched in the Web of Science, PubMed, and Google Scholar databases, and a literature review was conducted. The overview of the biological research, treatment status, potential therapeutic strategies, current research limitations, and future directions associated with PMP are presented, focuses on CRS-HIPEC therapy and alternative or combination therapy strategies, and emphasizes the clinical transformation prospects of potential therapeutic strategies such as mucolytic agents and targeted therapy. It provides a theoretical reference for the treatment of PMP and the main directions for future research.
腹膜假性黏液瘤（Pseudomyxoma peritonei, PMP）是一种罕见疾病，其特征为阑尾或其他器官的原发性黏液性肿瘤破裂后，黏液在腹膜广泛种植并大量分泌。细胞减灭术（Cytoreductive surgery, CRS）联合腹腔热灌注化疗（Hyperthermic intraperitoneal chemotherapy, HIPEC）是目前的首选治疗方法，具有优异的疗效和安全性，并在长期疾病控制和延长生存期方面取得突破性进展。然而，PMP的高复发率是其治疗中的关键挑战，这限制了多轮CRS-HIPEC的临床应用，且常规全身化疗效果不佳。因此，为耐药或复发性PMP患者开发替代疗法至关重要。通过在Web of Science、PubMed和Google Scholar数据库中检索与PMP研究进展及治疗相关的文献，并进行文献综述，本文概述了与PMP相关的生物学研究、治疗现状、潜在治疗策略、当前研究局限及未来方向，重点聚焦于CRS-HIPEC治疗及替代或联合治疗策略，并强调了黏液溶解剂和靶向治疗等潜在治疗策略的临床转化前景。这为PMP的治疗及未来研究的主要方向提供了理论参考。
Progress in Biological Research and Treatment of Pseudomyxoma Peritonei
肿瘤(癌症)患者之家